293 related articles for article (PubMed ID: 33928588)
1. siRNA Therapeutics in Ocular Diseases.
Moreno-Montañés J; Bleau AM; Martínez T; Vargas B; González MV; Jiménez AI
Methods Mol Biol; 2021; 2282():417-442. PubMed ID: 33928588
[TBL] [Abstract][Full Text] [Related]
2. Delivery of siRNA to the Eye: Protocol for a Feasibility Study to Assess Novel Delivery System for Topical Delivery of siRNA Therapeutics to the Ocular Surface.
Baran-Rachwalska P; Saffie-Siebert S; Moore CBT
Methods Mol Biol; 2021; 2282():443-453. PubMed ID: 33928589
[TBL] [Abstract][Full Text] [Related]
3. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.
Guzman-Aranguez A; Loma P; Pintor J
Br J Pharmacol; 2013 Oct; 170(4):730-47. PubMed ID: 23937539
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: Recent advancements and future perspectives.
Naik S; Shreya AB; Raychaudhuri R; Pandey A; Lewis SA; Hazarika M; Bhandary SV; Rao BSS; Mutalik S
Life Sci; 2021 Jan; 264():118712. PubMed ID: 33159955
[TBL] [Abstract][Full Text] [Related]
5. Nanoplatforms for Delivery of siRNA to the Eye.
Kataki MS; Kakoti BB; Jameson M; Solanki A; Hirani A; Pathak Y
Curr Pharm Des; 2015; 21(31):4587-93. PubMed ID: 26486145
[TBL] [Abstract][Full Text] [Related]
6. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
7. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
8. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
Holm A; Løvendorf MB; Kauppinen S
Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
[TBL] [Abstract][Full Text] [Related]
9. Nonviral pulmonary delivery of siRNA.
Merkel OM; Kissel T
Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
11. Strategies for silencing human disease using RNA interference.
Kim DH; Rossi JJ
Nat Rev Genet; 2007 Mar; 8(3):173-84. PubMed ID: 17304245
[TBL] [Abstract][Full Text] [Related]
12. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM; Yu AM
J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
[TBL] [Abstract][Full Text] [Related]
13. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
Zhou Y; Zhang C; Liang W
J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
[TBL] [Abstract][Full Text] [Related]
14. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders.
Campochiaro PA
Gene Ther; 2006 Mar; 13(6):559-62. PubMed ID: 16195702
[TBL] [Abstract][Full Text] [Related]
15. Preparation, Determination of Activity, and Biodistribution of Cholesterol-Containing Nuclease-Resistant siRNAs In Vivo.
Chernikov IV; Meschaninova MI; Chernolovskaya EL
Methods Mol Biol; 2020; 2115():57-77. PubMed ID: 32006394
[TBL] [Abstract][Full Text] [Related]
16. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Mangala LS; Rodriguez-Aguayo C; Bayraktar E; Jennings NB; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2021; 2372():157-168. PubMed ID: 34417750
[TBL] [Abstract][Full Text] [Related]
17. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
18. Chemical and structural modifications of RNAi therapeutics.
Ku SH; Jo SD; Lee YK; Kim K; Kim SH
Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
[TBL] [Abstract][Full Text] [Related]
19. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
